A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Clinicaltrials.gov ID
NCT05592626
Status
Recruiting
Study Type
Interventional, Phase 1/2
Sponsor
Marengo Therapeutics, Inc.
Start Date
January 4, 2023
Anticipated End Date
October 31, 2026
Study Contact
About the Study
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Conditions
Advanced Solid Tumors
Genital Neoplasm, Female
Urogenital Neoplasms
Lung Neoplasm
Neoplasms by Site
Papillomavirus Infection
Epstein-Barr Virus Infections
Carcinoma
Neoplasms
Vulvar Neoplasms
Vulvar Diseases
Abdominal Neoplasm
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2C4, Canada
About the Study
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Conditions
Advanced Solid Tumors
Genital Neoplasm, Female
Urogenital Neoplasms
Lung Neoplasm
Neoplasms by Site
Papillomavirus Infection
Epstein-Barr Virus Infections
Carcinoma
Neoplasms
Vulvar Neoplasms
Vulvar Diseases
Abdominal Neoplasm
Interventions
DRUG:
STAR0602
Locations in Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2C4, Canada